“Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.” The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.